Human T-cell leukaemia/lymphoma virus risk may be enhanced in some selected donor populations

Vox Sanguinis

Volumn 80, Issue 3, 2001, Pages 148-150

  Price, J ^a   Cant, B A ^a   Barbara, J A J ^a   Tedder, R S ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Human T cell leukaemia lymphona virus (HTLV) infection; Selective donor panels

Indexed keywords

HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; BLOOD COMPONENT; BLOOD DONOR; CAUCASIAN; CONTROLLED STUDY; ETHNIC GROUP; GENE AMPLIFICATION; HIGH RISK POPULATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROPREVALENCE; UNITED KINGDOM; VIRUS INFECTION;

EID: 0035323774     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2001.00030.x     Document Type: Article

References (12)

1. Murphy EL, Figueroa JP, Gibbs WN, Holding-Cobham M, Cranston B, Malley K, Bodner AJ, Alexander SS, Blatner WA: Human T-Lymphotropic Virus Type 1 (HTLV-1) Seroprevalence in Jamaica. Am J Epidemiol 1991; 133:1114-1124
2. Kaplan JE, Khabbaz RF: The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol 1993; 3:137-148
3. Okochi K, Sato H, Hinuma Y: A retrospective study on transmission of adult T cell leukaemia virus by blood transfusion: Seroconversion in recipients. Vox Sang 1984; 46:245-253
4. Tuke P, Luton P, Garson JA: Differential diagnosis of HTLV I and HTLV II infection by restriction enzyme analysis of 'nested' PCR product. J Virol Meth 1992; 40:P163-P174
5. Brennan M, Runganga J, Barbara JAJ, Contreras M, Tedder RS, Garson JA, Tuke PW, Mortimer PP, McAlpine L, Tosswill JHC: Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donors in North London. BMJ 1993; 307:1235-1239
6. Flanagan P, McAlpine L, Ramskill SJ, Smith AG, Eglin R, Parry JV, Mortimer PP: Evaluation of a combined HIV1/2 and HTLV-1/2 assay for screening blood donors. Vox Sang 1995; 68:220-224
7. Salker R, Tosswill JHC, Barbara JAJ, Runganga J, Contreras M, Tedder RS, Parra-Mejia N, Mortimer PP: HTLV-I/II antibodies in UK blood donors. Lancet 1990; 336:317
8. Vrielink H, Van der Poel CL, Reesnik HW: Efficacy of selected versus random blood donor screening for anti-HTLV-1 antibodies. Vox Sang 1995; 68:251-252
9. Couroucé A-M, Pillonel J, Lemaire J-M, Maniez M, Brunet J-B: Seroepidemiology of HTLV-1/11 in universal screening of blood donations in France. AIDS 1993; 7:841-847
10. Tynell E, Andersson S, Lithander E, Arnebourne M, Blomberg J, Hansson HB, Krook A, Nomberg M, Ramstedt K, Shanwell A, Bjorkman A: Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: Cost effectiveness analysis. BMJ 1998; 316:417
11. Chen J-W, Chin L-T, Yang C-M, Lin G-C, Lin W-S, Lu S-C, Chang I-E, Lin K-S: Evaluation of screening kits for the detection of antibodies of human T lymphotropic virus type I and II. J Biomed Lab Sci 1998; 10:29-38
12. Vrielink H, Reesink HW, Lelie PN: Relative sensitivity of four anti-HTLV I and HTLV II ELISAs: Abbott, Murex, Organon Teknika and Ortho. Transfusion 1997; 37(suppl):(Abstract S197) 50S